Nacubactam is under clinical development by Meiji Seika Pharma and currently in Phase I for Pseudomonas aeruginosa Infections. According to GlobalData, Phase I drugs for Pseudomonas aeruginosa Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nacubactam LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nacubactam overview
Nacubactam (RG6080, RO7079901) is under development for the treatment of complicated urinary tract infections including pyelonephritis and gram-negative bacterial infections such as Pseudomonas aeruginosa infections,hospital acquired bacterial pneumonia, ventilator associated bacterial pneumonia and complicated intra-abdominal infections. The drug candidate is administered intravenously. It is a new molecular entity (NME) and a diazabicyclooctane beta-lactamase inhibitor.
Meiji Seika Pharma overview
Meiji Seika Pharma, a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider. The company providing pharmaceutical, veterinary drugs and chemicals used for agriculture. The company offers Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest, Depromel and others. It operates manufacturing and development technologies, which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers products for human and veterinary care. It operates research center, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.
For a complete picture of Nacubactam’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.